GlobeNewswire

Award-Winning Smart Home Toolkit for Pro Installers Now Available from the Z-Wave Alliance

Dela

Evaluating the health and stability of a Z-Wave network, the Z-Wave Certified Installer Toolkit is the only globally available Z-Wave support device for smart home installers

 

AMSTERDAM, The Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ISE 2018 - Stand 9-F170  - The Z-Wave Alliance, a global membership organization dedicated to advancing the popular Z-Wave wireless smart home protocol, is now shipping the award-winning Z-Wave Certified Installer Toolkit (CIT) and demoing it to installers at ISE 2018. The CIT is a compact device, paired with unique software designed to make installation and testing of a Z-Wave smart home mesh network even easier for the pro installer community.

Z-Wave networks are generally easy to install but the Z-Wave Alliance has created a tool that helps integrators and smart home professionals ensure the quality and reliability of their work. The Z-Wave Certified Installer Toolkit is a maintenance and diagnostics device that provides information, both textually and graphically, on the health and stability of any Z-Wave network. The tool measures Z-Wave RF wireless signals, providing help with configuration or compatibility issues as they happen during setup or upgrading.

"We've heard extraordinary feedback on the CIT since we started shipping, winning several awards at CEDIA for our well-designed interface, brand agnostic approach and value-add for the integrator community," commented Mitchell Klein, Executive Director of the Z-Wave Alliance. "We are the only support and installation aide for Z-Wave networks that offers global availability with universal language support."

With the Alliance's database of all Z-Wave certified products, detailed information is available instantly on any certified product being installed. The toolkit provides access to everything from technical Z-Wave protocol information to the original owner's manual for each product that has gone through Z-Wave Plus certification. The toolkit is also field upgradable, making it future-proof for any new updates or advancements in products or the platform itself. The easy to navigate user interface is accessible through a web browser, making it available on a mobile phone, tablet or laptop computer on the road.

The Z-Wave Certified Installer Toolkit features include:

  • Comprehensive network diagnostics, device management and routing tables to ensure a solid mesh network is in place
  • A built-in web server that allows the toolkit to be placed in the customer's Z-Wave network and connected using any web browser through Wi-Fi.
  • Z-Wave Network Sniffer (ZNiffer) functionality - will display information about the Z-Wave transmissions taking place around the area where the tool is placed.
  • Spectrum Analyzer - will show basic information on the Z-Wave frequency range.
  • Global usage and language support; Wi-Fi and Ethernet connectivity with USB ports for expansion into future capabilities.

Integrators who purchase a toolkit at ISE 2018 will receive their first-year of Z-Wave Alliance membership for only one dollar. After purchase of a CIT, all software updates and upgrades will be available at no charge if the integrator remains a member in good standing. Additional toolkits will be available for purchase for all Alliance members. 

To learn more about how to sign up to be a Z-Wave integrator member and get free access to the Z-CIT and trainings, visit the website.

For more information on the Z-Wave Alliance, please visit http://z-wavealliance.org. For updates from Z-Wave at ISE 2018, follow the Z-Wave Alliance on FacebookTwitter and LinkedIn and with the #ISE2018 hashtag.

About Z-Wave
Z-Wave® technology is an open internationally recognized ITU standard (G.9959). It is the leading wireless home control technology in the market today, with over 2400 certified interoperable products worldwide.  Represented by the Z-Wave Alliance, and supported by more than 700 companies around the world, the standard is a key enabler of smart living solutions for home safety and security, energy, hospitality, office and light commercial applications.

Z-Wave® is a registered trademark of Sigma Designs (NASDAQ SIGM) and its subsidiaries in the United States and other countries.

About the Z-Wave Alliance
Formed in January 2005, the Z-Wave Alliance is a consortium of leading companies in the home technology space dedicated to solidifying Z-Wave as the standard for wireless home control products. The principal members include: ADT, Alarm.com, ASSA ABLOY, FIBARO, Huawei, Ingersoll Rand Nexia Intelligence, Jasco Products, Leedarson, LG Uplus, Nortek Security & Control, SmartThings and Sigma Designs.  Alliance members lead the home controls market, providing leading edge products and systems that deliver increased comfort, convenience, energy conservation, safety and security.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements about the benefits of Z-Wave Alliance membership, the benefits of the use of Z-Wave in product offerings, including the benefits of certain enhanced features of Z-Wave devices. Actual results may vary materially due to a number of factors including, but not limited to, consumer and customer acceptance of the Z-Wave Alliance (including its membership benefits), and Z-Wave technology in the relevant regions, the ability of the Z-Wave Alliance to compete with similar alliances in the industry and of the Z-Wave technology to compete with other technologies or related products in the market, if any, as well as other risks that are detailed from time to time in Z-Wave Alliance Members' reports to the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publically release or otherwise disclose the result of any revision to these forward-looking statements that may be made as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Press Contact: Caster Communications, Inc. at 401.792.7080
Ashley Daigneault ashley@castercomm.com (401) 651-3242
Alexandra Gil alex@castercomm.com (401) 792-7080

For digital images log on to www.castercomm.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Z-Wave Alliance via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum